Patents by Inventor Steven Shak

Steven Shak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosages for treatment with anti-ErbB2 antibodies
    Patent number: 6627196
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: September 30, 2003
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20030147884
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Application
    Filed: February 3, 2003
    Publication date: August 7, 2003
    Applicant: Genentech, Inc.
    Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
  • Anti-infective therapy
    Publication number: 20030044403
    Abstract: DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
    Type: Application
    Filed: November 7, 2001
    Publication date: March 6, 2003
    Applicant: Genentech, Inc.
    Inventor: Steven Shak
  • Human DNase I variants
    Patent number: 6348343
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Steven Shak, Jana S. Ulmer
  • Human DNase I variants
    Publication number: 20010041360
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
    Type: Application
    Filed: February 28, 2001
    Publication date: November 15, 2001
    Applicant: Genentech, Inc.
    Inventors: Robert A. Lazarus, Steven Shak, Jana S. Ulmer
  • Surfactant compositions and methods
    Patent number: 5876970
    Abstract: Stable lung surfactant compositions are provided, as well as methods for their preparation, modification, formulation, assay, and therapeutic use.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: March 2, 1999
    Assignee: Byk Gulden Lomberg Chemische Fabrik GmbH
    Inventors: Bradley J. Benson, John H. Frenz, Cynthia P. Quan, Steven Shak, Kathleen A. Shiffer, Michael C. Venuti, John T. Stults, David Lesikar